An Unexpected Masquerader: A Case of Acute Fulminant Colitis Secondary to Ulcerative Colitis

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1649
Author(s):  
Zaid Imam ◽  
Majd Khasawneh ◽  
Ismail Hader
Keyword(s):  
Ulcerative Colitis ◽  
Fulminant Colitis

scholarly journals Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis

Ulcers ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
J. Florholmen ◽  
G. Øverland ◽  
T. Olsen ◽  
R. Rismo ◽  
G. Cui ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Outcomes ◽  
Observation Time ◽  
Control Group ◽  
Infliximab Treatment ◽  
Fulminant Colitis ◽  
Superior Effect ◽  
Short And Long Term ◽  
Fulminant Ulcerative Colitis

The aim was to characterize short- and long-term clinical outcomes of infliximab in fulminant ulcerative colitis. Patients with severe ulcerative colitis meeting the criteria of fulminant colitis after 3 days of glucocorticosteroid treatment were randomized to control or additional induction therapy of infliximab followed by an on demand/maintenance therapy of infliximab. Twenty six patients with fulminant colitis were equally randomized. At Day 7, ten patients in the control group and none in the infliximab group were in the need of colectomy (). Due to superior effect of infliximab, patients in the control group were of ethical reasons transformed to infliximab treatment instead of performing colectomy. The probability to avoid colectomy was 0.66 with a median observation time of 52 months and a maximal of 91 months. The addition of azathioprine reduced the risk of late colectomy. We conclude that infliximab is effective in preventing early and late colectomy in fulminant colitis.

scholarly journals All That Bleeds Is Not Infliximab-Refractory Ulcerative Colitis

2009 ◽  
Vol 23 (2) ◽  
pp. 91-92
Author(s):  
JK Law ◽  
B Salh ◽  
EM Yoshida
Keyword(s):  
Ulcerative Colitis ◽  
Gastrointestinal Hemorrhage ◽  
Clinical Remission ◽  
Biological Agents ◽  
Fulminant Colitis ◽  
Lower Gastrointestinal Hemorrhage ◽  
Severe Ulcerative Colitis ◽  
Intravenous Steroids ◽  
New Diagnosis

The role of biological agents in moderate to severe ulcerative colitis has been shown to be effective in the induction of clinical remission. However, the role of infliximab therapy for induction of remission in patients with fulminant colitis is debatable. A case of a hospitalized patient with a new diagnosis of severe ulcerative colitis refractory to intravenous steroids is presented. The patient was treated with infliximab and discharged with clinical remission, but subsequently presented back to hospital with a lower gastrointestinal hemorrhage.

Sign in / Sign up

Export Citation Format

Share Document